These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 38778340)

  • 21. BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells.
    Sanagawa A; Hotta Y; Mori N; Tomita N; Kataoka T; Tohkin M; Kimura K
    Anticancer Drugs; 2021 Nov; 32(10):1076-1083. PubMed ID: 34232935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
    King AJ; Arnone MR; Bleam MR; Moss KG; Yang J; Fedorowicz KE; Smitheman KN; Erhardt JA; Hughes-Earle A; Kane-Carson LS; Sinnamon RH; Qi H; Rheault TR; Uehling DE; Laquerre SG
    PLoS One; 2013; 8(7):e67583. PubMed ID: 23844038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
    Johnson DB; Flaherty KT; Weber JS; Infante JR; Kim KB; Kefford RF; Hamid O; Schuchter L; Cebon J; Sharfman WH; McWilliams RR; Sznol M; Lawrence DP; Gibney GT; Burris HA; Falchook GS; Algazi A; Lewis K; Long GV; Patel K; Ibrahim N; Sun P; Little S; Cunningham E; Sosman JA; Daud A; Gonzalez R
    J Clin Oncol; 2014 Nov; 32(33):3697-704. PubMed ID: 25287827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
    Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
    Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib.
    Mondru AK; Wilkinson B; Aljasir MA; Alrumayh A; Greaves G; Emmett M; Albohairi S; Pritchard-Jones R; Cross MJ
    FEBS Lett; 2024 Aug; 598(16):2011-2027. PubMed ID: 38977937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
    N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.
    Gonzalez-Cao M; Mayo de Las Casas C; Oramas J; Berciano-Guerrero MA; de la Cruz L; Cerezuela P; Arance A; Muñoz-Couselo E; Espinosa E; Puertolas T; Diaz Beveridge R; Ochenduszko S; Villanueva MJ; Basterretxea L; Bellido L; Rodriguez D; Campos B; Montagut C; Drozdowskyj A; Molina MA; Lopez-Martin JA; Berrocal A
    Nat Commun; 2021 Dec; 12(1):7008. PubMed ID: 34853302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.
    Hamis SJ; Kapelyukh Y; McLaren A; Henderson CJ; Roland Wolf C; Chaplain MAJ
    Br J Cancer; 2021 Nov; 125(11):1552-1560. PubMed ID: 34621046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT; Infante JR; Daud A; Gonzalez R; Kefford RF; Sosman J; Hamid O; Schuchter L; Cebon J; Ibrahim N; Kudchadkar R; Burris HA; Falchook G; Algazi A; Lewis K; Long GV; Puzanov I; Lebowitz P; Singh A; Little S; Sun P; Allred A; Ouellet D; Kim KB; Patel K; Weber J
    N Engl J Med; 2012 Nov; 367(18):1694-703. PubMed ID: 23020132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
    Schreuer M; Meersseman G; Van Den Herrewegen S; Jansen Y; Chevolet I; Bott A; Wilgenhof S; Seremet T; Jacobs B; Buyl R; Maertens G; Neyns B
    J Transl Med; 2016 Apr; 14():95. PubMed ID: 27095081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.
    Takano K; Munehira Y; Hatanaka M; Murakami R; Shibata Y; Shida T; Takeuchi K; Takechi S; Tabata T; Shimada T; Kishikawa S; Matsui Y; Ubukata O; Seki T; Kaneta Y
    Mol Cancer Ther; 2023 Mar; 22(3):317-332. PubMed ID: 36622773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
    Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
    Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist).
    Sakai T
    Pharmacol Ther; 2022 Aug; 236():108234. PubMed ID: 35732246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
    Borst A; Haferkamp S; Grimm J; Rösch M; Zhu G; Guo S; Li C; Gao T; Meierjohann S; Schrama D; Houben R
    Cancer Lett; 2017 Sep; 404():70-78. PubMed ID: 28720543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
    Lassen A; Atefi M; Robert L; Wong DJ; Cerniglia M; Comin-Anduix B; Ribas A
    Mol Cancer; 2014 Apr; 13():83. PubMed ID: 24735930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.